Dtsch Med Wochenschr 2014; 139(06): 243-246
DOI: 10.1055/s-0033-1359988
Hämatologie und Onkologie | Commentary
Hämatologie
© Georg Thieme Verlag KG Stuttgart · New York

Chronische myeloproliferative Neoplasien

Chronic myeloproliferative neoplasms
M. Griesshammer
1   Hämatologie und Onkologie, Hämostaseologie und Palliativmedizin am Johannes-Wesling-Klinikum Minden
,
K. Döhner
2   Klinik für Innere Medizin III, Zentrum für Innere Medizin, Universitätsklinikum Ulm
› Author Affiliations
Further Information

Publication History

Publication Date:
28 January 2014 (online)

    Permissions and Reprints

Schlüsselwörter

myeloproliferative Neoplasien - essenzielle Thrombozythämie - Polycythaemia vera - Myelofibrose

Keywords

myeloproliferative neoplasms - essential thrombocythemia - polycythemia vera - myelofibrosis
 

  • Literatur

  • 1 Aumann K, Frey AV, May AM et al. Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia. Blood 2013; 122: 93-99
    CrossrefGoogle Scholar
  • 2 Barbui T, Thiele J, Passamonti F et al. Survival and risk of leukemic transformation in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study on 1104 patients. J Clin Oncol 2011; 29: 3179-3284
    CrossrefPubMedGoogle Scholar
  • 3 Barbui T, Thiele J, Vannucchi AM et al. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia 2013; 27: 1953-1958
    CrossrefGoogle Scholar
  • 4 Cervantes F, Kiladjian JJ, Niederwieser D et al. Long-term safety, efficacy, and survival from COMFORT-II, a phase III study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelfibrosis (MF). ASH Annual Meeting Abstracts 2012; 120 (21) 801
    Google Scholar
  • 5 Harrison C, Kiladjian JJ, Al-Ali HK et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787-798
    CrossrefGoogle Scholar
  • 6 Klampfl T, Gisslinger H, Ashot SH et al. Frequent mutations in the calreticulin gene CALR in myeloproliferative neoplasms. ASH; 2013. Late-breaking abstract session; # LBA-1 http://www.hematology.org/
    Google Scholar
  • 7 Kröger N, Holler E, Kobbe G et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264-5270
    CrossrefGoogle Scholar
  • 8 Marchioli R, Finazzi G, Specchia G et al. CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013; 368: 22-33
    CrossrefGoogle Scholar
  • 9 Nangalia J, Massie C, Baxter EJ et al. The genomic landscape of myeloproliferative neoplasms: somatic calr mutations in the majority of JAK2-wildtype patients. ASH; 2013. Late-breaking abstract session; # LBA-2 http://www.hematology.org/
    Google Scholar
  • 10 Thiele J, Kvasnicka HM, Dietrich H et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol 2005; 20: 879-889
    Google Scholar
  • 11 Vardiman JW, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951
    CrossrefGoogle Scholar
  • 12 Verstovsek S, Mesa R, Gotlib J et al. Long-Term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reduction in spleen volume, improvement in quality of life, and overall survival advantage in COMFORT-I. ASH Annual Meeting Abstracts 2012; 120 (21) 800
    Google Scholar
  • 13 Verstovsek S, Mesa RA, Gotlib J et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807
    CrossrefGoogle Scholar